United States Patent 12,370,189 (Guaifenesin / Dextromethorphan / Naproxen Bilayer Tablet): Claim Scope and Patent Landscape
What does US 12,370,189 claim, in plain scope terms?
US Patent 12,370,189 claims a specific fixed-dose, bilayer, 12-hour pharmaceutical tablet that combines three active ingredients and separates particular excipients by layer.
Core actives and dose anchors (claims 1 and 5)
A composition comprising the following dose levels:
| Component |
Required amount (approx.) |
Claim role |
| Guaifenesin |
~600 mg |
fixed-dose component |
| Dextromethorphan (or salt) |
~30 mg |
fixed-dose component |
| Naproxen (or salt) |
~110 mg |
fixed-dose component |
| Hypromellose |
≥25 mg |
sustained/excipient positioning requirement (by layer) |
| Hydroxyethyl cellulose (HEC) |
≥12.25 mg |
sustained/excipient positioning requirement (by layer) |
12-hour therapeutic effect requirement (all independent claim paths)
The claims require that the composition “provides a therapeutic effect in respect of each of guaifenesin, naproxen, and dextromethorphan for 12 hours.” This ties claim validity to a release profile / performance claim element across all three actives.
Bilayer structure with layer-specific excipient exclusion (claims 1 and 8)
The tablet must be a bilayer tablet with an immediate release layer that contains:
- Naproxen ~110 mg
- Guaifenesin ≥95 mg
- Dextromethorphan ≥7.5 mg
- No hypromellose in the immediate release layer
- No hydroxyethyl cellulose in the immediate release layer
This creates a structural limitation plus a compositional segregation requirement. The immediate release layer is defined by what it must contain and by what it must not contain.
Immediate release layer definition is “partial dose” (not all actives in layer 1)
The independent claims do not demand that the immediate release layer contains the full dose of each active. Instead, they demand minimums for guaifenesin and dextromethorphan:
- guaifenesin immediate release: ≥95 mg (out of ~600 mg)
- dextromethorphan immediate release: ≥7.5 mg (out of ~30 mg)
- naproxen immediate release: about 110 mg (effectively all of the naproxen dose)
That combination (full naproxen in layer 1, minimum fractions of the other two actives in layer 1) is a distinctive scope anchor.
How do the dependent claims narrow or expand the scope?
The claim set you provided has two main “routes”: a base trilayer-less excipient arrangement (claims 1 and its descendants), and an additional surfactant/buffer embodiment (claims 2–5) plus hypromellose/HEC content control (claims 6–8).
Route A: Hypromellose + HEC present in the overall tablet, excluded from layer 1
-
Claim 1 requires overall hypromellose ≥25 mg and HEC ≥12.25 mg, but states immediate release layer contains none of hypromellose and none of HEC.
-
Claim 8 restates that exclusion:
- immediate release layer contains none of hypromellose
- immediate release layer contains none of HEC
This creates a repeated infringement hook: even if a competitor uses the same actives and same 12-hour profile, placing any of these polymers into layer 1 can avoid literal infringement if claim language is enforced strictly by layer composition.
Route B: Adds sodium lauryl sulfate (SLS) + sodium bicarbonate (NaHCO3)
-
Claim 2 adds:
- sodium lauryl sulfate and sodium bicarbonate
-
Claim 3 limits sodium bicarbonate amount:
-
Claim 4 gives a layer assignment:
- immediate release layer contains all of the sodium lauryl sulfate
- immediate release layer contains about 60 mg of sodium bicarbonate
-
Claim 5 is the modified independent claim that requires:
- SLS present
- NaHCO3 about 60 mg
- and it also fixes the same bilayer immediate release composition concept, but with layer assignment for SLS and NaHCO3.
Route B further controls polymer levels (claims 6–7)
Operationally, claim 6 ties to total-tablet weight (not just minimums). Claim 7 ties to absolute mass.
Where are the “hard edges” in the claim language that limit design-arounds?
From a freedom-to-operate standpoint, the sharpest literal constraints are the combined presence-and-exclusion rules plus fixed-dose performance.
1) No hypromellose and no hydroxyethyl cellulose in the immediate release layer
This is not a general sustained-release concept; it is a layer-specific exclusion.
- If a competitor formulation includes any hypromellose or HEC in layer 1, the product may fall outside literal scope of claims 1/8.
- The independent claim also requires hypromellose and HEC to be present in the overall tablet (≥25 mg and ≥12.25 mg), so moving these polymers to layer 2 is expected in any literal-infringement candidate.
2) Immediate release layer contains all naproxen
The claim states immediate release layer containing “about 110 mg of the naproxen.” That makes naproxen placement unusually restrictive. If a competitor disperses naproxen into both layers, literal infringement is less likely (depending on rounding and “about” interpretation).
3) Immediate release layer has minimum fractions of the other actives
- guaifenesin in layer 1: at least 95 mg
- dextromethorphan in layer 1: at least 7.5 mg
A design-around can potentially lower initial layer fractions below these minima while maintaining the 12-hour overall performance requirement. Whether that works depends on how the competitor establishes the required therapeutic effect for 12 hours for each active.
4) 12-hour therapeutic effect is across all three actives
The therapeutic effect requirement is drafted as applying to guaifenesin, naproxen, and dextromethorphan for 12 hours. A competitor could aim for:
- 12-hour naproxen and 12-hour guaifenesin, but not 12-hour dextromethorphan (or vice versa)
- or use a different release mechanism that delivers less than a 12-hour “therapeutic effect” for one active
This element can be used both for validity and infringement arguments because it is an outcome requirement tied to dosage form design.
5) The SLS/NaHCO3 embodiment depends on layer assignment
For claims 4 and 5:
- all SLS in immediate release layer
- NaHCO3 about 60 mg in immediate release layer
A competitor could attempt to:
- place only part of SLS into layer 1
- alter NaHCO3 amount away from about 60 mg
- place NaHCO3 outside the immediate release layer
Those moves target literal differences.
How does claim structure affect practical claim coverage (infringement posture)?
The patent has:
- One independent composition claim (claim 1 in your excerpt) based on hypromellose/HEC overall presence and exclusion from immediate layer.
- A second independent composition claim (claim 5 in your excerpt) that adds SLS and NaHCO3 and locks in layer assignment for those excipients.
- Dependent claims that narrow polymer levels (by weight and by minimum mass) and reinforce exclusion from layer 1 (claim 8).
That structure means literal infringement analysis typically turns on:
- whether the tablet is a bilayer with an immediate release layer as claimed
- whether naproxen is essentially confined to that immediate layer
- whether hypromellose/HEC appear in the immediate layer
- whether SLS/NaHCO3 appear and are confined to the immediate layer in the claim-locked amounts (for claim 5/4 path)
What is the competitive patent landscape risk, based on claim-level technology pattern?
Who is most likely to collide with these claims (by formulation approach)?
Collision risk concentrates around developers of:
- fixed-dose multi-API cold/flu or pain-relief combinations containing guaifenesin + dextromethorphan + naproxen
- extended-release or bilayer-release tablet technologies where polymers such as hypromellose and HEC manage the second-layer release while the immediate layer contains most of the “fast” dose fractions
- formulations that use SLS and sodium bicarbonate for wetting, solubilization, or pH buffering in a fast-release layer
Within that subset, a product that also demonstrates 12-hour performance for all three actives is most exposed.
Likely “near-by” competitors in technical space (not adjudicated against this patent)
Given only the claims text you provided, the nearest design space includes bilayer or multilayer tablets combining:
- an immediate layer with a fast fraction of at least two actives and essentially all of naproxen
- exclusion of certain viscosity-enhancing polymers from layer 1
- polymer-controlled release from a second layer that contains hypromellose and/or HEC
- optional inclusion of SLS and NaHCO3 in the immediate layer
What are common design-arounds against this specific claim drafting?
The claims give a roadmap for avoidance.
Design-around levers
-
Place hypromellose and/or HEC in the immediate release layer
- would aim to break the “none in immediate release layer” limitation.
-
Move part of naproxen out of the immediate release layer
- would aim to break the “immediate release layer containing about 110 mg naproxen” requirement.
-
Reduce immediate layer minimum fractions for guaifenesin and dextromethorphan
- aim to keep layer-1 guaifenesin below 95 mg and/or dextromethorphan below 7.5 mg while maintaining 12-hour performance overall.
-
Alter SLS/NaHCO3 placement or level (for claim 5 route)
- move SLS off layer 1
- move NaHCO3 off layer 1
- alter NaHCO3 from about 60 mg
-
Re-engineer release to avoid “12-hour therapeutic effect” for one or more actives
- riskier legally but targets the outcome limitation.
What does an enforcement strategy likely look like?
A patent holder with this claim set can assert across two independent claim paths:
-
Claim 1 route: bilayer with immediate layer devoid of hypromellose/HEC, containing the required naproxen and minimum fractions of guaifenesin/dextromethorphan, with overall ≥25 mg hypromellose and ≥12.25 mg HEC, and 12-hour therapeutic effect for each active.
-
Claim 5 route: same base but with SLS + NaHCO3 present, with SLS and about 60 mg NaHCO3 in the immediate release layer, and polymer levels constrained (via dependent claims 6–7 if those are used).
In litigation, the fact pattern usually turns on:
- product build (bilayer, immediate vs second layer)
- compositional mapping by layer (polymer/excipient presence or absence)
- quantitative dosing by layer (naproxen, guaifenesin, dextromethorphan minima)
- pharmacokinetic or clinical data demonstrating “12 hours” therapeutic effect for each active
Key Takeaways
- US 12,370,189 claims a specific bilayer tablet with fixed-dose actives (~600 mg guaifenesin, ~30 mg dextromethorphan, ~110 mg naproxen) and a 12-hour therapeutic effect across all three actives.
- The most binding feature is layer-specific excipient exclusion: the immediate release layer contains none of hypromellose and none of hydroxyethyl cellulose, while those polymers must be present in the overall tablet (≥25 mg and ≥12.25 mg).
- A second independent claim path adds sodium lauryl sulfate and sodium bicarbonate (~60 mg) with layer assignment: all SLS and about 60 mg NaHCO3 are in the immediate release layer.
- Design-around risk is highest for competitors using bilayer structures that concentrate naproxen in the immediate layer, deliver minimum initial fractions of guaifenesin and dextromethorphan, and manage extended release with hypromellose/HEC confined to the second layer.
FAQs
1) Does the patent require all naproxen to be in the immediate release layer?
Yes. The immediate release layer is required to contain about 110 mg naproxen, aligning with the full claimed dose.
2) Can a competitor avoid infringement by adding hypromellose or HEC into the immediate release layer?
That is a direct literal strategy against the “none in the immediate release layer” limitation in claims 1 and 8.
3) Are guaifenesin and dextromethorphan required to be fully in the immediate layer?
No. The claim sets minimum amounts in the immediate layer (guaifenesin ≥95 mg, dextromethorphan ≥7.5 mg) rather than full-dose placement.
4) Is sodium lauryl sulfate and sodium bicarbonate optional?
For the base claim route (claim 1): yes. For the second independent route (claim 5): no, they are required, with about 60 mg NaHCO3 and layer placement constraints.
5) Does “12 hours” apply to each active separately?
Yes. The claims require a therapeutic effect in respect of guaifenesin, naproxen, and dextromethorphan for 12 hours.
References
- United States Patent 12,370,189. Claim text as provided in the prompt.
